Niagen Bioscience (NASDAQ:NAGE) Announces Earnings Results

Niagen Bioscience (NASDAQ:NAGE) issued its quarterly earnings results on Wednesday. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01), FiscalAI reports. The firm had revenue of $27.19 million for the quarter. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%.

Niagen Bioscience Trading Down 16.5%

Shares of NAGE stock traded down $0.41 during trading hours on Thursday, hitting $2.10. 780,097 shares of the company’s stock were exchanged, compared to its average volume of 837,470. The company has a market capitalization of $167.65 million, a PE ratio of 11.70 and a beta of 2.12. Niagen Bioscience has a 12-month low of $2.07 and a 12-month high of $7.55. The business’s 50 day simple moving average is $2.81 and its 200-day simple moving average is $3.87.

Institutional Investors Weigh In On Niagen Bioscience

Institutional investors have recently made changes to their positions in the business. SteelPeak Wealth LLC bought a new stake in shares of Niagen Bioscience in the 1st quarter valued at about $14,875,000. Arrowstreet Capital Limited Partnership boosted its holdings in Niagen Bioscience by 47.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock valued at $10,489,000 after acquiring an additional 761,685 shares during the period. Tieton Capital Management LLC bought a new position in Niagen Bioscience during the 2nd quarter worth approximately $6,407,000. Sei Investments Co. grew its position in Niagen Bioscience by 155.6% during the 1st quarter. Sei Investments Co. now owns 971,574 shares of the company’s stock worth $4,285,000 after acquiring an additional 591,495 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Niagen Bioscience by 45.4% during the 1st quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock worth $5,860,000 after acquiring an additional 414,725 shares during the last quarter. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Analysts Set New Price Targets

NAGE has been the subject of several research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, October 15th. Canaccord Genuity Group reduced their target price on Niagen Bioscience from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, October 30th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Niagen Bioscience presently has a consensus rating of “Buy” and an average price target of $10.00.

Key Stories Impacting Niagen Bioscience

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Niagen outlined plans for a three-year, 5,000-participant Mass General Brigham trial and is targeting early 2027 commercialization of NR malate. These are potential growth catalysts, though the trial and product launch remain future initiatives. Niagen trial and commercialization plans
• Neutral Sentiment: Q3 net sales were $27.2 million, including $23.3 million from Tru Niagen; direct-to-consumer sales on the company’s website rose 13% year over year, and gross margin was 62%. Q3 2026 financial results
• Negative Sentiment: The company posted a Q3 loss of $0.01 per share, matching consensus but down from earnings of $0.05 a year earlier. Zacks also reported that revenue missed estimates, adding to concerns about near-term performance. Q3 earnings and revenue report
• Negative Sentiment: HC Wainwright cut its 2027 quarterly EPS estimates across Q1–Q4, including lowering its Q1 view from $0.03 profit to a $0.01 loss. Broad reductions signal a less favorable near-term earnings outlook. Niagen analyst estimate coverage

Niagen Bioscience Company Profile

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.